Dubai Approves 3rd Pfizer Shot For These Categories
- Publish date: Thursday، 02 September 2021
- Related articles
- First Case Of Omicron Variant Spotted In Saudi Arabia
- Shaping The Future ... More Than 50 Doctors Recieved Golden UAE Visa
- UAE: 50 National Projects to Be Announced in September
The Dubai Health Authority (DHA) approved offering a third dose of the Pfizer-BioNTech COVID-19 vaccine to people with moderately to severely compromised immune systems.
فيديو ذات صلة
This browser does not support the video element.
Those above the age of 12 and included in the below categories can take the 3rd dose:
- People with moderately to severely compromised immune systems
- Individuals who have an active tumor and hematologic malignancy or have recently received treatment for the same
- Recipients of a solid organ transplant or patients who have undergone Hematopoietic stem cell transplantation (HSCT)
- People who suffer from a severe case of primary immunodeficiency
- Patients with advanced or untreated HIV
- Patients undergoing active treatment with agents that are immunosuppressive or immunomodulatory
The #Dubai Health Authority (@DHA_Dubai) announces today that it will begin administering a third dose of the Pfizer-BioNTech COVID-19 vaccine to people with moderately to severely compromised immune systems.https://t.co/xVlaB4NuCf pic.twitter.com/fdNYRVYQct
— Dubai Media Office (@DXBMediaOffice) September 1, 2021
However, in some cases patients suffering from immune-related diseases might not need a third dose of the COVID-19 vaccine.
Patients should first consult their treating physicians in a government or private hospital in Dubai in order to get their case assessed.
If a third dose must be administered, their physicians will book the appointment for them in the same hospital.
Those with physicians outside UAE need to confirm their eligibility for the third dose, they will have to book a consultation appointment with a DHA family medicine doctor or request a telemedicine consultation ( Doctor for Every Citizen) by calling 800 342.